nach oben

Medical Oncology

Erschienen in:

01.03.2012 | Original Paper

The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells

verfasst von: Hong-yun Wang, Gao-fei Xiong, Ji-xiang Zhang, Hong Xu, Wu-hua Guo, Jiang-jing Xu, Xiang-yang Xiong

Erschienen in: Medical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We investigated the role of XPD in cell apoptosis of hepatoma and its relationship with p53 during the regulation of hepatoma bio-behavior. RT–PCR and Western blot were used to detect the expression levels of XPD, p53, c-myc, and cdk2. The cell apoptosis and cell cycle were analyzed with flow cytometry. Compared with the control cells, XPD-transfected cells displayed a lower viability and higher apoptosis rate. A decreased expression of p53 gene was detected in XPD-transfected cells. In contrast, both c-myc and cdk2 showed increased expressions of mRNAs and proteins in the transfected cells. Our results indicate that XPD may play an important role in cell apoptosis of hepatoma by inducing an over-expression of p53, but suppressing expressions of c-myc and cdk2.

Emmert S, Leibeling D, Rünger TM. Syndromes with genetic instability: model diseases for (skin) cancerogenesis. J Dtsch Dermatol Ges. 2006;4:721–31.PubMedCrossRef

Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res. 2005;3:531–9.PubMedCrossRef

Nakajima S, Lan L, Kanno S, Takao M, Yamamoto K, Eker AP, Yasui A. UV light-induced DNA damage and tolerance for the survival of nucleotide excision repair-deficient human cells. J Biol Chem. 2004;279:46674–7.PubMedCrossRef

Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie. 2003;85:1101–11.PubMedCrossRef

Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature. 1993;365:852–5.PubMedCrossRef

Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini AM, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nature Genet. 1998;20:184–8.PubMedCrossRef

Lainé JP, Mocquet V, Bonfanti M, Braun C, Egly JM, Brousset P. Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair (Amst). 2007;6:1264–70.CrossRef

Robles AI, Harris CC. p53-mediated apoptosis and genomic instability diseases. Acta Oncol. 2001;40:696–701.PubMedCrossRef

Askin DF, Diehl-Jones WL. The neonatal liver: part III: pathophysiology of liver dysfunction. Neonatal Netw. 2003;22:5–15.PubMed

10.

Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol. 1998;72:266–72.PubMed

11.

Jaitovich-Groisman I, Benlimame N, Slagle BL, Perez MH, Alpert L, Song DJ, Fotouhi-Ardakani N, Galipeau J, Alaoui-Jamali MA. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J Biol Chem. 2001;276:14124–32.PubMed

12.

Uhring M, Poterszman A. DNA helicases and human diseases. Med Sci (Paris). 2006;22:1087–94.CrossRef

13.

Capovilla A, Arbuthnot P. Nucleotide excision repair by extracts of human fetal hepatocytes. FEBS Lett. 2002;518:144–8.PubMedCrossRef

14.

Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene. 1999;18:4681–8.PubMedCrossRef

15.

Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer. 1999;80:875–9.PubMedCrossRef

16.

Giebler HA, Lemasson I, Nyborg JK. p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation. Mol Cell Biol. 2000;20:4849–58.PubMedCrossRef

17.

Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ Jr. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol. 2000;20:3705–14.PubMedCrossRef

18.

Léveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM, Wasylyk B. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 1996;15:1615–24.PubMed

19.

Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10:1219–32.PubMedCrossRef

20.

Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, Kahn A, Perret C. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001;61:3245–9.PubMed

21.

Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J Hepatol. 2004;41:815–22.PubMedCrossRef

22.

Hamajima N, Saito T, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Okuma K, Tajima K. Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients. J Epidemiol. 2002;12:229–36.PubMedCrossRef

23.

Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, Reinberg D, Levens D. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell. 2001;104:353–63.PubMedCrossRef

24.

Liu J, He L, Collins I, Ge H, Libutti D, Li J, Egly JM, Levens D. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell. 2000;5:331–41.PubMedCrossRef

25.

Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol. 2005;25:147–61.PubMedCrossRef

26.

Adamczewski JP, Rossignol M, Tassan JP, Nigg EA, Moncollin V, Egly JM. MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J. 1996;15:1877–84.PubMed

27.

Lolli G, Johnson LN. Recognition of Cdk2 by Cdk7. Proteins. 2007;67:1048–59.PubMedCrossRef

28.

Chen J, Larochelle S, Li X, Suter B. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature. 2003;424:228–32.PubMedCrossRef

Titel: The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells
verfasst von: Hong-yun Wang
Gao-fei Xiong
Ji-xiang Zhang
Hong Xu
Wu-hua Guo
Jiang-jing Xu
Xiang-yang Xiong
Publikationsdatum: 01.03.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-9818-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma

Cardiac stunning as a manifestation of ATRA differentiation syndrome in acute promyelocytic leukemia

Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft

Lung fluorescence imaging to evaluate tumor metastasis induced by AQP5 expression in murine model

Correlation of major histocompatibility complex class I related A (MICA) polymorphism with the risk of developing breast cancer

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie